Search

Erectile dysfunction (ED) has been reported to be associated with inflammation. This study investigated the effects of tumor necrosis factor alpha (TNF-[alpha]) inhibitor etanercept on penile neuronal nitric oxide synthase (nNOS) and endothelial nitric oxide synthase (eNOS) expressions, testosterone concentrations, neurogenic and endothelium-dependent relaxations of corpus cavernosum (CC), and circulating and cavernosal levels of inflammatory markers in aged rats. Animals were separated into control, aged, and etanercept-treated aged groups. Aged rats displayed significantly increased serum and cavernosal TNF- [alpha], C-reactive protein (CRP), monocyte chemoattractant protein-1 (MCP-1) and intercellular adhesion molecule (ICAM-1) levels, and decreased penile nNOS and eNOS expressions and serum testosterone levels compared with controls. In etanercept-treated aged group, NOS expressions were similar to that of the control group. The circulating and cavernosal concentrations of TNF-[alpha], CRP, MCP-1, ICAM-1, and testosterone were also normalized by etanercept. Neurogenic and endothelium-dependent relaxant responses significantly decreased in aged rats and etanercept treatment markedly improved these relaxation responses. Our findings indicate that aging decreases penile NOS expression, neurogenic and endothelium-dependent relaxations of CC, and also suppresses serum testosterone levels by inducing inflammatory response that may contribute to the development of ED. TNF-[alpha] antagonism may be a novel strategy to treat aging-associated ED. Key words: erectile dysfunction, aging, etanercept, TNF-[alpha], inflammation, eNOS, nNOS. On a rapporte que la dysfonction erectile (DE) est associee a l'inflammation. Dans ces travaux chez des rats ages, nous avons etudie les effets de l'etanercept, un inhibiteur du facteur de necrose tumorale alpha (TNF-[alpha]), sur l'expression penienne de l'oxyde nitrique synthase neuronale (nNOS) et de l'oxyde nitrique synthase endotheliale (eNOS), les concentrations de testosterone, la relaxation des corps carveneux (CC) neurogenique et dependante de l'endothelium ainsi que les taux caverneux et circulants de marqueurs de l'inflammation. Nous avons reparti les animaux dans des groupes de rats temoins, ages et ages avec administration d'etanercept. Par rapport aux temoins, les rats ages ont presente une augmentation marquee des taux seriques et caverneux de TNF-[alpha], de proteine C reactive (PCR), de proteine 1 chimio-attractive de monocytes (MCP-1) et de molecule d'adherence intercellulaire (ICAM-1), ainsi qu'une diminution marquee de l'expression penienne de nNOS et de eNOS, ainsi que des taux de testosterone serique. L'expression de NOS etait semblable dans le groupe age avec etanercept et dans groupe temoin. Les concentrations circulantes et caverneuses de TNF-[alpha], de PCR, de MCP-1, d'ICAM-1 et de testosterone revenaient aussi a la normale sous etanercept. Les reactions de relaxation neurogeniques et dependantes de l'endothelium s'attenuaient nettement chez les rats ages, et l'administration d'etanercept permettait d'ameliorer ces reactions de relaxation de facon notable. Nos resultats indiquent que le vieillissement entrame une diminution de l'expression penienne des NOS, de la relaxation neurogene et dependante de l'endothelium des CC, et aussi qu'il entrame une diminution des taux de testosterone en provoquant une reaction inflammatoire qui pourrait contribuer a l'apparition de la DE. L'antagonisme de TNF-[alpha] pourrait constituer une nouvelle strategie visant a traiter la DE associee au vieillissement. [Traduit par la Redaction] Mots-cles: dysfonction erectile, vieillissement, etanercept, TNF-[alpha], inflammation, eNOS, nNOS., Introduction Nitric oxide (NO), generated by both neuronal nitric oxide synthase (nNOS) and endothelial nitric oxide synthase (eNOS), is one of the main vasodilator messengers in the process of erection [...]

ABSTRACT Background: In two previous phase 3 studies, up to 60 weeks of etanercept therapy significantly improved the symptoms of psoriasis and was well tolerated. Objective: To evaluate the long-term [...]

A study was conducted to evaluate and compare the efficacy and safety of two biological agents - ustekinumab and etanercept for the treatment of moderate-to-severe psoriasis. Results indicated that a dose of 45 or 90 mg of ustekinumab was found to be far more effective and beneficial than etanercept.

ABSTRACT Pemphigus vulgaris is an autoimmune disease characterized by intraepidermal blister formation. The treatment of pemphigus vulgaris is generally regarded as difficult. Corticosteroids, the drug class of first choice, often [...]

ABSTRACT Introduction: Psoriasis is one of several systemic diseases that presents chiefly with cutaneous symptoms and has the potential to negatively impact patients' overall health and quality of life. Physicians [...]

ABSTRACT Treatment of patients with moderate-severe psoriasis and/or psoriatic arthritis includes systemic biologic, antimetabolite, and immunosuppressive therapy. However, adverse events such as serious infectious complications must be considered before starting [...]

ABSTRACT Psoriasis is an immunologic disorder mediated by T cells and proinflammatory cytokines. Novel biologic therapies, targeted at key pathogenic steps, have been developed and provide efficacy without the potential [...]

ABSTRACT Psoriasis and psoriatic arthritis (PsA) are chronic inflammatory disorders. Efalizumab targets several T-cell interactions central to psoriasis immunopathogenesis. Etanercept and infliximab are antitumor necrosis factor (anti-TNF) agents that modify [...]

ABSTRACT Introduction: Palmoplantar pustulosis (PPP) is a chronic, recurrent and difficult to treat skin condition characterized by the presence of pustules, erythema, and hyperkeratosis on palms and soles. Methods: Fifteen [...]

An alteration of the intestinal barrier is considered to represent an early step in pathogenesis of Crohn's disease. The integrity of intestinal barrier function is guaranteed among other factors by enterocyte fight junction (TJ) proteins. Clinical and experimental data indicate the TNF-[alpha] to be the major responsible factor for these defects. In the present study we investigated the very early effects of DNBS-ethanol colitis on ileal enterocyte TJ proteins [occludin, zonula occludens-1 (ZO-1), claudin-2] in controls, mice treated with infliximab (IFX) or with etanercept (ETC), and in knockout mice for the TNF-[alpha] receptor 1 (TNFR-1-/ ). Circulating TNF-[alpha] levels were effectively reduced by IFX and ETC (P < 0.01, both) at 3 and at 6 h. DNBS colitis induced disappearance of occludin and ZO-1 from enterocyte cell-cell contact, whereas claudin-2, absent under control conditions, appeared in the ileal epithelium. These alterations were prevented equally by both treatments, IFX and ETC, and in [TNFR-1.sup.-/-] animals. DNBS colitis induced a very rapid loss of occludin and ZO-1 from ileal TJ together with an upregulation of claudin-2. Our data are consistent with the hypothesis that TNF-[alpha] is involved in early TJ rearrangement and that its effects are mediated through TNFR-1. Despite clinical differences, both anti-TNF treatments were equally effective in the present setting. infliximab; etanercept; occludin; zonula occludens-1; claudin-2

A study analyzes the efficacy and safety of etanercept in children and adolescents with moderate-to-severe plaque psoriasis. Findings reveal the capability of etanercept in significantly reducing disease severity in children and adolescents with moderate-to-severe plaque psoriasis.

Byline: Abhishek. De, Tanumay. Raychaudhury, Murlidhar. Rajagopalan, Aarti. Sarda, Nidhi. Sharma Sir, A 43-year-old male patient presented with generalized pruritic, erythematous to violaceous plaques and hypopigmented scaly ill-defined patches. The [...]

Abstract The Experience Diagnosing, Understanding Care, and Treatment with Enbrel[R] (EDUCATE) trial is a phase IV, 24-week, multicenter, open-label study of etanercept 50 mg weekly in the treatment of psoriatic [...]

Modeling exposure-response relationships adds significant value to comprehending and interpreting both efficacy and safety data. An exposure-response model was developed using generalized nonlinear mixed-effects methodologies to correlate etanercept exposure with [...]

Majority of patients with Wegener's granulomatosis have disease flares after conventional medications are tapered and there are no consistently safe, effective treatment for the maintenance of remission. A randomized, placebo-controlled trial is conducted to evaluate etanercept for the maintenance of remission in patients with Wegener's granulomatosis.